Cargando…
Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment
The value of protocol liver graft biopsies with good liver function was evaluated in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). A total of 250 protocol liver biopsy reports from 182 PSC and PBC patients were compared. Overall histopathological findings a...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758011/ https://www.ncbi.nlm.nih.gov/pubmed/35029206 http://dx.doi.org/10.1097/MD.0000000000028509 |
_version_ | 1784632809348923392 |
---|---|
author | Vannas, Marko Arola, Johanna Nordin, Arno Isoniemi, Helena |
author_facet | Vannas, Marko Arola, Johanna Nordin, Arno Isoniemi, Helena |
author_sort | Vannas, Marko |
collection | PubMed |
description | The value of protocol liver graft biopsies with good liver function was evaluated in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). A total of 250 protocol liver biopsy reports from 182 PSC and PBC patients were compared. Overall histopathological findings and those leading to changes in immunosuppression therapy were retrospectively analyzed. The mean time to first protocol biopsy after transplantation was 5.5 (±4.5) years for PSC patients and 9.3 (±6.6) years for PBC patients. More than 1 abnormal histopathological parameter was found in 43% and 62% of PSC and PBC patients, respectively. However, the histology was interpreted as normal by the pathologist in 78% of PSC and 60% of PBC patients. Immunosuppression therapy was reduced in 10% and increased in 6% patients due to protocol biopsy findings. Biopsies leading to increased immunosuppression therapy had more portal (P = .004), endothelial (P = .008), interphase (P = .021), and lobular (P = .000) inflammation. Mild histopathological findings were frequently found in the protocol biopsies despite the normal biochemistry. PBC patients had more histological abnormalities than those transplanted due to PSC; however, PBC patients had longer follow-up times. Immunosuppression therapy could be safely increased or decreased according to protocol biopsy findings after multidisciplinary meeting discussions. |
format | Online Article Text |
id | pubmed-8758011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-87580112022-01-19 Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment Vannas, Marko Arola, Johanna Nordin, Arno Isoniemi, Helena Medicine (Baltimore) 4500 The value of protocol liver graft biopsies with good liver function was evaluated in patients with primary sclerosing cholangitis (PSC) or primary biliary cholangitis (PBC). A total of 250 protocol liver biopsy reports from 182 PSC and PBC patients were compared. Overall histopathological findings and those leading to changes in immunosuppression therapy were retrospectively analyzed. The mean time to first protocol biopsy after transplantation was 5.5 (±4.5) years for PSC patients and 9.3 (±6.6) years for PBC patients. More than 1 abnormal histopathological parameter was found in 43% and 62% of PSC and PBC patients, respectively. However, the histology was interpreted as normal by the pathologist in 78% of PSC and 60% of PBC patients. Immunosuppression therapy was reduced in 10% and increased in 6% patients due to protocol biopsy findings. Biopsies leading to increased immunosuppression therapy had more portal (P = .004), endothelial (P = .008), interphase (P = .021), and lobular (P = .000) inflammation. Mild histopathological findings were frequently found in the protocol biopsies despite the normal biochemistry. PBC patients had more histological abnormalities than those transplanted due to PSC; however, PBC patients had longer follow-up times. Immunosuppression therapy could be safely increased or decreased according to protocol biopsy findings after multidisciplinary meeting discussions. Lippincott Williams & Wilkins 2022-01-14 /pmc/articles/PMC8758011/ /pubmed/35029206 http://dx.doi.org/10.1097/MD.0000000000028509 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) |
spellingShingle | 4500 Vannas, Marko Arola, Johanna Nordin, Arno Isoniemi, Helena Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment |
title | Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment |
title_full | Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment |
title_fullStr | Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment |
title_full_unstemmed | Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment |
title_short | Value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: A step toward personalized immunosuppressive treatment |
title_sort | value of posttransplant protocol biopsies in 2 biliary autoimmune liver diseases: a step toward personalized immunosuppressive treatment |
topic | 4500 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758011/ https://www.ncbi.nlm.nih.gov/pubmed/35029206 http://dx.doi.org/10.1097/MD.0000000000028509 |
work_keys_str_mv | AT vannasmarko valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment AT arolajohanna valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment AT nordinarno valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment AT isoniemihelena valueofposttransplantprotocolbiopsiesin2biliaryautoimmuneliverdiseasesasteptowardpersonalizedimmunosuppressivetreatment |